山科智能最新一期业绩显示，截至2025一季报，公司营业总收入1.11亿元、同比减少17.62%，归属净利 润939.51万元，同比减少43.28%，扣非净利润818.98万元，同比减少46.93%，流动比率3.634、速动比率 2.870、资产负债率18.22%。 天眼查商业履历信息显示，杭州山科智能科技股份有限公司，成立于1999年，位于杭州市，是一家以从 事仪器仪表制造业为主的企业。企业注册资本10048.664万人民币，实缴资本10048.664万人民币。公司 法定代表人为钱炳炯。 通过天眼查大数据分析，杭州山科智能科技股份有限公司共对外投资了18家企业，参与招投标项目1399 次，知识产权方面有商标信息4条，专利信息113条，此外企业还拥有行政许可79个。 金融界消息 截至2025年8月1日收盘，山科智能（300897）报收于27.3元，上涨3.02%，换手率4.79%， 成交量4.20万手，成交金额1.14亿元。 资金流向方面，今日主力资金净流入1637.28万元，占比成交额14.42%。其中，超大单净流入278.47万 元、占成交额2.45%，大单净流入1358.81万元、占成交额11.97%，中 ...

三星医疗最新一期业绩显示，截至2025一季报，公司营业总收入36.31亿元、同比增长20.03%，归属净 利润4.89亿元，同比增长34.33%，扣非净利润4.60亿元，同比增长22.62%，流动比率1.804、速动比率 1.277、资产负债率47.79%。 天眼查商业履历信息显示，宁波三星医疗电气股份有限公司，成立于2007年，位于宁波市，是一家以从 事仪器仪表制造业为主的企业。企业注册资本141100.6571万人民币，实缴资本40050万人民币。公司法 定代表人为沈国英。 金融界消息 截至2025年8月1日收盘，三星医疗（601567）报收于22.67元，上涨0.8%，换手率2.15%， 成交量30.22万手，成交金额6.88亿元。 资金流向方面，今日主力资金净流入4599.40万元，占比成交额6.69%。其中，超大单净流入3033.94万 元、占成交额4.41%，大单净流入1565.46万元、占成交额2.28%，中单净流出流出1969.72万元、占成交 额2.86%，小单净流出2629.68万元、占成交额3.82%。 通过天眼查大数据分析，宁波三星医疗电气股份有限公司共对外投资了19家企业，参与招投标 ...

金融界消息 截至2025年8月1日收盘，烽火通信（600498）报收于22.11元，下跌1.56%，换手率3.57%， 成交量41.69万手，成交金额9.22亿元。 资金流向方面，今日主力资金净流入6946.73万元，占比成交额7.53%。其中，超大单净流入6609.54万 元、占成交额7.17%，大单净流入337.19万元、占成交额0.37%，中单净流出流出728.03万元、占成交额 0.79%，小单净流出6218.70万元、占成交额6.74%。 来源：金融界 烽火通信最新一期业绩显示，截至2025一季报，公司营业总收入40.49亿元、同比减少19.97%，归属净 利润5519.69万元，同比增长33.08%，扣非净利润5394.59万元，同比增长28.96%，流动比率1.288、速动 比率0.863、资产负债率62.87%。 天眼查商业履历信息显示，烽火通信科技股份有限公司，成立于1999年，位于武汉市，是一家以从事仪 器仪表制造业为主的企业。企业注册资本118549.1768万人民币，实缴资本32825万人民币。公司法定代 表人为曾军。 通过天眼查大数据分析，烽火通信科技股份有限公司共对外投资了39家企 ...

Core Insights - The article discusses the recent government procurement intentions for laboratory instruments, highlighting a total of 28 items with a budget of 213 million yuan [2][3]. Procurement Overview - The procurement includes various advanced instruments such as small animal MRI, nanofiber prototype machines, ultracentrifuges, high-content imaging systems, and 300kV cryo-electron microscopes, with expected procurement dates between August and December 2025 [3][4]. - The total budget for these instruments is 213 million yuan, indicating significant investment in biomedical research capabilities [2][3]. Instrument Details - **Small Animal MRI**: Designed for high-precision imaging of small animals, widely used in biomedical research [3][4]. - **Nanofiber Prototype Machine**: Aimed at producing nanofibers, with a budget of 5 million yuan [4][6]. - **Ultracentrifuge**: Capable of speeds exceeding 100,000 rpm, featuring advanced monitoring and control systems [6][7]. - **High-Content Imaging System**: Equipped with multiple laser sources and advanced imaging capabilities, budgeted at 400 million yuan [6][7]. - **300kV Cryo-Electron Microscope**: Designed for structural analysis of biological macromolecules, with a budget of 4.5 million yuan [6][7]. Additional Instruments - **High-Throughput Sequencer**: Expected to process large volumes of samples efficiently, with a capacity of 300-600Gb/run [7][8]. - **Automated Nucleic Acid Analyzer**: Integrates extraction, amplification, and analysis processes, ensuring high-quality results [7][8]. - **Mass Spectrometry Equipment**: Aimed at protein identification and analysis, with a budget of 1.25 million yuan [7][8]. - **Liquid Chromatography Systems**: Two units planned for procurement, designed to meet high-pressure and flow rate requirements [7][8]. Conclusion - The procurement intentions reflect a strategic focus on enhancing research capabilities in the biomedical field, with substantial investments in advanced laboratory instruments [2][3][4].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025年7⽉7⽇，上海第三人民中级法院公开终结强制清算公告。 公告称： 就 上海川岭仪器仪表合作公司 破产清算一案，因客观上无法进行全面清算，本院应清算组申请，依照《中 华人民共和国公司法》第二百三十九条之规定，于 2 0 2 5年5月8日裁定终结破产程序。 上海市第三中级人民法院 民事 裁 定 书 (2025) 沪 03 强清 61 号之一 申请人:上海川岭仪器仪表合作公司清算组。 组长:沈紫华。 2025年2月5日,上海川岭仪器仪表合作公司(以下简称川 岭公司)清算组向本院提交清算报告,称川岭公司已停止经营, 清算组除接管到川岭公司都分证照、坦章、财务账册、原始会计 凭证等资料外,未接管到任何财产,截至报告时所有税收债权均 已清偿完毕,无社保债权,亦无任何债权人申报债权。鉴于川岭 公司无任何财产,客观上无法进行全面清算,且该公司无法清偿 强制清算费用,已符合终结强制清算程序的法定条件。 本院认为,川岭公司清算组的清算报告依法可予确认,鉴于 川岭公司清算组虽然接管到川岭公司部分证照、印章、 ...

Group 1 - Haier U+ Smart Technology (Beijing) Co., Ltd. and Qingdao Haier Technology Co., Ltd. have obtained a patent for "Control Method and Device for Smart Devices, Storage Medium, and Electronic Device," with authorization announcement number CN115407674B, applied on August 2022 [1] - Haier U+ Smart Technology (Beijing) Co., Ltd. was established in 2015, located in Beijing, with a registered capital of 143 million RMB, and has participated in 16 bidding projects, holding 1 trademark and 1,904 patents [1] - Qingdao Haier Technology Co., Ltd. was established in 2000, located in Qingdao, with a registered capital of 80 million RMB, participating in 75 bidding projects, holding 198 trademarks and 3,737 patents [1] Group 2 - Haier Smart Home Co., Ltd. was established in 1994, located in Qingdao, with a registered capital of approximately 943.81 million RMB, having invested in 58 companies and participated in 1,704 bidding projects, holding 285 trademarks and 5,000 patents [2]

Core Viewpoint - The company plans to utilize temporarily idle self-owned funds for cash management, with a maximum amount of RMB 350 million, to enhance the utilization rate of idle funds and increase returns for the company and its shareholders [1][2]. Group 1: Investment Purpose - The investment aims to improve the utilization rate of idle self-owned funds while ensuring the normal operation and safety of funds for the company and its subsidiaries, thereby saving financial costs and increasing cash asset returns [1][2]. Group 2: Investment Products - The company will invest in low-risk, highly liquid, short-term financial products, including but not limited to structured deposits, agreed deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][3]. Group 3: Cash Management Limit and Duration - The planned cash management limit is set at a maximum of RMB 350 million, with a usage period not exceeding 12 months, allowing for the funds to be used in a rolling manner within this limit and timeframe [2][3]. Group 4: Impact on Daily Operations - The use of idle self-owned funds for cash management will not affect the normal cash turnover needs or the main business development of the company and its subsidiaries, while also providing better investment returns for the company and its shareholders [2][3]. Group 5: Risk Control Measures - The company will implement risk control measures, including selecting quality financial institutions, defining cash management amounts and periods, and conducting regular assessments of investment products to mitigate potential market risks [3][4]. Group 6: Review Process - The proposal for cash management was approved in the board meeting held on July 31, 2025, and does not require submission to the shareholders' meeting for approval, allowing for immediate implementation following board approval [4].

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate returns for the company and its shareholders [4][5][6]. Summary by Sections 1. Basic Information on Raised Funds - The company was approved by the China Securities Regulatory Commission to publicly issue 17 million shares at a price of 24.80 RMB per share, raising a total of 421.6 million RMB, with a net amount of 374.48 million RMB after deducting issuance costs [1]. 2. Investment Project Status - The company has modified its investment projects, reallocating funds from the "Experimental Analysis Instrument Consumables Production Project" to the "Trace and Ultra-trace Element Analysis ICP-MS and Online Analysis System Production and R&D Project" [2]. - As of November 14, 2023, the company has approved the conclusion of certain projects and will use surplus funds of 70 million RMB for new projects, including 50 million RMB for a gas chromatography-mass spectrometry project and 20 million RMB for an ICP spectrometer project [2]. 3. Cash Management Plan - The company aims to use up to 130 million RMB of temporarily idle raised funds for cash management, with a maximum investment period of 12 months [4][5]. - The investment will focus on low-risk, high-liquidity financial products, ensuring that the funds are not used for pledging or securities investment [4][6]. 4. Decision-Making and Governance - The board of directors has authorized the chairman to make investment decisions within the approved limits and timeframe, with the finance department responsible for implementation [5][6]. - The decision is valid for 12 months from the date of board approval [5]. 5. Impact on Daily Operations - The cash management plan will not affect the company's normal operations or the progress of investment projects, and it is expected to generate additional returns for the company and its shareholders [4][5]. 6. Verification by Sponsor Institution - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and does not alter the intended use of raised funds, thus supporting the company's interests [6].

北京莱伯泰科仪器股份有限公司 信息披露暂缓与豁免管理制度 北京莱伯泰科仪器股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范北京莱伯泰科仪器股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，督促公司依法合规履行信息披露义务，保护投资者的合法权益，根据《中 华人民共和国证券法》、《上海证券交易所科创板股票上市规则》（以下简称"《上市 规则》"）、《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规范 运作》（以下简称"《规范运作指引》"）、《上市公司信息披露管理办法》、《上市 公司信息披露暂缓与豁免管理规定》、《北京莱伯泰科仪器股份有限公司章程》（以下 简称"《公司章程》"）、《北京莱伯泰科仪器股份有限公司信息披露管理办法》等规 定，制定本制度。 第二条 信息披露义务人按照《上市规则》《规范运作指引》及其他相关法律法规、 规范性文件的规定，办理信息披露暂缓、豁免业务的，适用本制度。 第三条 信息披露义务人应当披露的信息存在《上市规则》《规范运作指引》及上 海证券交易所其他相关业务规则中规定的可暂缓、豁免信息披露的情形的，无须向上海 证券交易所申请，由信息披露义务人自行审 ...

Core Points - The company, 莱伯泰科, announced the approval of a proposal to use temporarily idle raised funds for cash management, with a maximum amount of up to RMB 130 million [2] Group 1 - The board meeting is scheduled for July 31, 2025, to review the cash management proposal [2] - The cash management will involve purchasing low-risk, high-liquidity principal-protected financial products, including but not limited to structured deposits, agreed deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2] - The approval allows for the funds to be used within a 12-month period from the date of board approval, with the possibility of rolling over the funds within the specified limit and timeframe [2]